POEMS syndrome: The matter-of-fact approach

Current Opinion in Neurology

Volumn 24, Issue 5, 2011, Pages 491-496

  Scarlato, Marina ^a   Previtali, Stefano C ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Autologous peripheral blood stem cell transplantation; lenalidomide; plasma cell dyscrasia; polyneuropathy; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CORTICOSTEROID; IMMUNOGLOBULIN; LENALIDOMIDE; MELPHALAN; THALIDOMIDE; VASCULOTROPIN;

AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CLINICAL FEATURE; DISEASE MARKER; HUMAN; NEUROTOXICITY; PATHOGENESIS; POEMS SYNDROME; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW;

BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; HUMANS; POEMS SYNDROME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052481481     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328348e107     Document Type: Review

References (55)

1. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood 2003; 101:2496-2506. (Pubitemid 36857604)
2. Dispenzieri A. POEMS syndrome. Blood Rev 2007; 21:285-299. (Pubitemid 47498680)
3. Sonneveld P, Jongen JL. Dealing with neuropathy in plasma-cell dyscrasias. Hematology Am Soc Hematol Educ Program 2010; 2010:423-430.
4. Kuwabara S, Dispenzieri A, Arimura K, Misawa S. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev 2008; 4:CD006828.
5. Nakanishi T, Sobue I, Toyokura Y, et al. The Crow-Fukase syndrome: a study of 102 cases in Japan. Neurology 1984; 34:712-720. (Pubitemid 14107067)
6. Soubrier MJ, Dubost JJ, Sauvezie BJ. POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS Syndrome. Am J Med 1994; 97:543-553. (Pubitemid 24370886)
7. Miralles GD, O'Fallon JR, Talley NJ. Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. N Engl J Med 1992; 327:1919-1923. (Pubitemid 23006967)
8. Isose S, Misawa S, Kanai K, et al. POEMS syndrome with Guillan-Barre syndrome-like acute onset: a case report and review of neurological progression in 30 cases. J Neurol Neurosurg Psychiatry 2011; 82:678-680.
9. Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 1999; 85:706-717. (Pubitemid 29075292)
10. Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 2009; 16:236-246.
11. Kihara Y, Hori H, Murakami H, et al. A case of POEMS syndrome associated with reactive amyloidosis and Waldenströ m's macroglobulinaemia. J Intern Med 2002; 252:255-258.
12. Sung JY, Kuwabara S, Ogawara K, et al. Patterns of nerve conduction abnormalities in POEMS syndrome. Muscle Nerve 2002; 26:189-193. (Pubitemid 34832800)
13. Kaushik M, Pulido JS, Abreu R, et al. Ocular findings in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome. Ophthalmology 2011; 118:778-782.
14. Koike H, Iijima M, Mori K, et al. Neuropathic pain correlates with myelinated fibre loss and cytokine profile in POEMS syndrome. J Neurol Neurosurg Psychiatry 2008; 79:1171-1179.
15. Sobue G, Doyu M, Watanabe M, et al. Extensive demyelinating changes in the peripheral nerves of Crow-Fukase syndrome: a pathological study of one autopsied case. Acta Neuropathol 1992; 84:171-177.
16. Scarlato M, Previtali SC, Carpo M, et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain 2005; 128 (Pt 8):1911-1920. (Pubitemid 41373663)
17. Vital C, Vital A, Ferrer X, et al. Crow-Fukase (POEMS) syndrome: a study of peripheral nerve biopsy in five new cases. J Peripher Nerv Syst 2003; 8:136-144. (Pubitemid 37075744)
18. Adams D, Said G. Ultrastructural characterisation of the M protein in nerve biopsy of patients with POEMS syndrome. J Neurol Neurosurg Psychiatry 1998; 64:809-812. (Pubitemid 28274421)
19. Dupont SA, Dispenzieri A, Mauermann ML, et al. Cerebral infarction in POEMS syndrome: incidence, risk factors, and imaging characteristics. Neurology 2009; 73:1308-1312.
20. Ropper AH, Raje NS, Lawrimore TM, et al. Case records of the Massachusetts General Hospital. Case 7-2010.
21. Briani C, Fedrigo M, Manara R, et al. Pachymeningeal involvement in POEMS syndrome: MRI and histopathological study. J Neurol Neurosurg Psychiatry (in press).
22. Barete S, Mouawad R, Choquet S, et al. Skin manifestations and vascular endothelial growth factor levels in POEMS syndrome: impact of autologous hematopoietic stem cell transplantation. Arch Dermatol 2010; 146:615-623.
23. Phillips JA, Dixon JE, Richardson JB, et al. Glomeruloid hemangioma leading to a diagnosis of POEMS syndrome. J Am Acad Dermatol 2006; 55:149-152. (Pubitemid 43867040)
24. Kulkarni GB, Mahadevan A, Taly AB, et al. Clinicopathological profile of polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes (POEMS) syndrome. J Clin Neurosci 2011; 18:356-360.
25. Nakamoto Y, Imai H, Yasuda T, et al. A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome. Nephrol Dial Transplant 1999; 14:2370-2378. (Pubitemid 29462474)
26. Watanabe O, Arimura K, Kitajima I, et al. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 1996; 347: 702. (Pubitemid 26076167)
27. Ferrara N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell 2010; 21:687-690.
28. Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P. Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 2009; 89:607-648.
29. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling: in control of vascular function. Nat Rev Mol Cell Biol 2006; 7:359-371.
30. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011; 364:656-665.
31. Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005; 8:85-92. (Pubitemid 41236736)
32. Hashiguchi T, Arimura K, Matsumuro K, et al. Highly concentrated vascular endothelial growth factor in platelets in Crow-Fukase syndrome. Muscle Nerve 2000; 23:1051-1056. (Pubitemid 30437114)
33. Watanabe O, Maruyama I, Arimura K, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve 1998; 21:1390-1397. (Pubitemid 28453125)
34. Nobile-Orazio E, Terenghi F, Giannotta C, et al. Serum VEGF levels in POEMS syndrome and in immune-mediated neuropathies. Neurology 2009; 72:1024-1026.
35. Briani C, Fabrizi GM, Ruggero S, et al. Vascular endothelial growth factor helps differentiate neuropathies in rare plasma cell dyscrasias. Muscle Nerve 2011; 43:164-167.
36. Michizono K, Umehara F, Hashiguchi T, et al. Circulating levels of MMP-1,-2,-3,-9, and TIMP-1 are increased in POEMS syndrome. Neurology 2001; 56:807-810. (Pubitemid 32240111)
37. Rovira M, Carreras E, Bladé J, et al. Dramatic improvement of POEMS syndrome following autologous haematopoietic cell transplantation. Br J Haematol 2001; 115:373-375. (Pubitemid 34203505)
38. Dyck PJ, Engelstad J, Dispenzieri A. Vascular endothelial growth factor and POEMS. Neurology 2006; 66:10-12. (Pubitemid 43739583)
39. Kuwabara S, Misawa S, Kanai K, et al. Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. J Neurol Neurosurg Psychiatry 2008; 79:1255-1257.
40. Dispenzieri A, Klein CJ, Mauermann ML. Lenalidomide therapy in a patient with POEMS syndrome. Blood 2007; 110:1075-1076. (Pubitemid 47267453)
41. Badros A, Porter N, Zimrin A. Bevacizumab therapy for POEMS syndrome. Blood 2005; 106:1135.
42. Kaygusuz I, Tezcan H, Cetiner M, et al. Bortezomib: a new therapeutic option for POEMS syndrome. Eur J Haematol 2010; 84:175-177.
43. Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev 2010; 24 Suppl 1:S13-S19.
44. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108:3289-3294.
45. Chen M, Doherty SD, Hsu S. Innovative uses of thalidomide. Dermatol Clin 2010; 28:577-586.
46. Jaccard A, Royer B, Bordessoule D, et al. High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome. Blood 2002; 99:3057-3059. (Pubitemid 34525399)
47. Dispenzieri A, Moreno-Aspitia A, Suarez GA, et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 2004; 104:3400-3407. (Pubitemid 39507165)
48. Kuwabara S, Misawa S, Kanai K, et al. Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome. Neurology 2008; 71:1691-1695.
49. Giglia F, Chiapparini L, Fariselli L, et al. POEMS syndrome: relapse after successful autologous peripheral blood stem cell transplantation. Neuromuscul Disord 2007; 17:980-982. (Pubitemid 350137726)
50. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364:1046-1060.
51. Kanai K, Kuwabara S, Misawa S, Hattori T. Failure of treatment with anti-VEGF monoclonal antibody for long-standing POEMS syndrome. Intern Med 2007; 46:311-313. (Pubitemid 46488401)
52. Dietrich PY, Duchosal MA. Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome. Ann Oncol 2008; 19:595.
53. Straume O, Bergheim J, Ernst P. Bevacizumab therapy for POEMS syndrome. Blood 2006; 107:4972-4973 [author reply 4973-4974].
54. Tang X, Shi X, Sun A, et al. Successful bortezomib-based treatment in POEMS syndrome. Eur J Haematol 2009; 83:609-610.
55. Ohguchi H, Ohba R, Onishi Y, et al. Successful treatment with bortezomib and thalidomide for POEMS syndrome. Ann Hematol 2010 [Epub ahead of print].